TScan Therapeutics (TCRX) EBITDA (2020 - 2026)

TScan Therapeutics (TCRX) has reported EBITDA for 7 consecutive years, with -$30.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 21.11% year-over-year to -$30.5 million in Q2 2026; TTM through Jun 2026 was -$120.5 million, a 16.43% increase from a year earlier, with the FY2025 full-year figure at -$135.8 million, down 0.74% from the prior year.
• EBITDA was -$30.5 million for Q2 2026 at TScan Therapeutics, down from -$29.1 million in the prior quarter.
• Over five years, EBITDA peaked at -$15.2 million in Q2 2022 and troughed at -$38.7 million in Q2 2025.
• A 5-year average of -$27.2 million and a median of -$26.9 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 104.13% in 2022 and soared 35.01% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$18.6 million in 2022, then declined by 14.52% to -$21.4 million in 2023, then tumbled by 71.9% to -$36.7 million in 2024, then soared by 35.01% to -$23.9 million in 2025, then fell by 27.81% to -$30.5 million in 2026.
• The last three EBITDA figures came in at -$30.5 million (Q2 2026), -$29.1 million (Q1 2026), and -$23.9 million (Q4 2025), per Business Quant data.